PRODIGE 24: Complete Statistical Analysis of mFOLFIRINOX in Resected Pancreatic Adenocarcinoma

1. Trial at a Glance

PRODIGE 24 was a phase 3 randomized trial evaluating adjuvant chemotherapy with mFOLFIRINOX compared with gemcitabine in patients with resected pancreatic adenocarcinoma.

2. Clinical Question

3. Trial Design

4. Endpoints

5. Planned Analysis

The registry identifies disease-free survival (DFS) at 3 years as the primary endpoint. Disease-free survival is a time-to-event outcome that typically evaluates the time from a defined starting point, such as randomization or treatment assignment, until disease recurrence or another prespecified event.

Time-to-event endpoints are commonly analyzed using methods such as Kaplan-Meier estimation to describe event-free probabilities over time, log-rank testing to compare groups, and regression models such as Cox proportional-hazards models to estimate relative treatment effects. The registry does not report posted statistical analyses or endpoint estimates on ClinicalTrials.gov.

6. Statistical Methodology

Randomized comparison

Randomization creates the framework for comparing treatment groups while reducing the influence of measured and unmeasured baseline differences. In a parallel design, participants remain associated with their assigned treatment group for the primary comparison.

Disease-free survival analysis

DFS is a time-to-event endpoint. Analysis must account for participants who have not experienced the event by the end of follow-up through censoring methods.

Hazard ratios and survival models

For time-to-event outcomes, a hazard ratio is commonly used to summarize the relative event rate between groups over the analyzed follow-up period. The interpretation depends on the statistical model and assumptions used.

7. Statistical Methods Explained

Why use disease-free survival as an endpoint?

Disease-free survival captures events related to recurrence or disease status and can provide an earlier assessment of treatment effects than overall survival in some clinical settings.

Why is randomization important?

Randomization allows treatment groups to be compared using a design intended to minimize systematic differences between groups.

What does censoring mean?

Censoring occurs when a participant's event status is not observed by the analysis cutoff. Statistical methods incorporate available follow-up information without assuming the exact future event time.

Why are confidence intervals important?

Confidence intervals describe uncertainty around an estimated treatment effect. They provide information about statistical precision rather than the range of outcomes experienced by individual patients.

Why is the p-value not an effect-size measure?

A p-value addresses compatibility between observed data and a statistical hypothesis. It does not describe the magnitude or clinical importance of an effect.

8. Limitations

• The registry does not report posted statistical analyses or numerical efficacy results.
• Important analytical details such as statistical models, handling of missing data, and analysis populations are not reported in the registry record.
• Time-to-event outcomes depend on follow-up duration and censoring patterns.

9. Why This Trial Matters Statistically

10. Limitations and Interpretation Issues

The interpretation of a randomized clinical trial depends on the prespecified statistical analysis plan, endpoint definitions, follow-up completeness, and analysis population. The registry record for PRODIGE 24 identifies the design and endpoint framework but does not report statistical analysis outputs.

11. Sources

• ClinicalTrials.gov record: NCT01526135
• PubMed: Publication record
• PubMed: Publication record